US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

Despite the challenges, many people with psoriatic arthritis lead full, active lives through effective treatment and self-management strategies. Staying informed about the condition helps patients ...

Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520, today announced that the UK’s ...

When I was diagnosed with psoriatic arthritis, my daughters were 3 and 5—active, energetic, and always wanting to play make-believe. The first thought that crushed me was, “Will I still be ...

New study shows a subset of psoriatic arthritis patients can achieve long-term remission without DMARDs. Learn who benefits and why it matters for PsA management.

Biocon Biologics receives UK MHRA marketing approval for Yesintek, biosimilar of ustekinumab: Bengaluru Monday, May 26, 2025, 11:30 Hrs [IST] Biocon Biologics, a fully integrated ...

Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi™ is indicated for the treatment of several serious ...

Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as ...